Verrier | European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy566.P5708...
A.A. Marum, et al. | International Journal of Cardiology 2018 We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects. Methods: Flecainide was delivered via intratracheal administration at...
May 23, 2018 - San Francisco, CA At the SF Business Times Bay Area Biotech Forum, InCarda’s Dr. Grace Colon presented a company update to investors where she discussed the clinical challenges of Atrial Fibrillation and InCarda’s novel approach to treating it called, InRhythm (oral flecainide...
Verrier | J Cardiovascular Electrophysiology 2018, In Press ...
Belardinelli | Circulation 2017; 136:A16836 Oral and IV routes for delivery of flecainide (FLEC) for acute cardioversion of atrial fibrillation (AF) have drawbacks: high doses (150-300 mg) and 2- to 4- hours wait time for cardioversion with oral dosing and hospitalization for IV administration. Studies in...
Belardinelli | Circulation 2017; 136:A16888 Flecainide (FLEC) is effective for cardioversion of recentonset atrial fibrillation (AF). In dogs and pigs intratracheal instillation of FLEC is effective in terminating episodes of AF within minutes. The present study is part of a drug development program to use inhaled...
Flecainide administered via oral inhalation is well tolerated and elicits ECG changes suggestive of rapid drug delivery to heart Brisbane, California, June 7, 2017 – InCarda Therapeutics, Inc. (InCarda), a privately held biopharmaceutical company developing therapies for acute cardiovascular conditions via the inhalation route, today...